Takeda Pharmaceutical (TKPHF) Equity Income (2017 - 2025)
Historic Equity Income for Takeda Pharmaceutical (TKPHF) over the last 9 years, with Q4 2025 value amounting to $28.8 million.
- Takeda Pharmaceutical's Equity Income rose 17352.94% to $28.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $50.6 million, marking a year-over-year decrease of 2759.26%. This contributed to the annual value of -$26.2 million for FY2025, which is 15829.95% down from last year.
- Latest data reveals that Takeda Pharmaceutical reported Equity Income of $28.8 million as of Q4 2025, which was up 17352.94% from $10.2 million recorded in Q3 2025.
- In the past 5 years, Takeda Pharmaceutical's Equity Income ranged from a high of $76.4 million in Q1 2021 and a low of -$28.8 million during Q3 2021
- In the last 5 years, Takeda Pharmaceutical's Equity Income had a median value of -$214134.2 in 2025 and averaged $5.7 million.
- Per our database at Business Quant, Takeda Pharmaceutical's Equity Income crashed by 47084.54% in 2021 and then surged by 76800.08% in 2024.
- Over the past 5 years, Takeda Pharmaceutical's Equity Income (Quarter) stood at -$15.2 million in 2021, then increased by 17.82% to -$12.5 million in 2022, then dropped by 24.41% to -$15.6 million in 2023, then surged by 167.64% to $10.5 million in 2024, then soared by 173.53% to $28.8 million in 2025.
- Its Equity Income was $28.8 million in Q4 2025, compared to $10.2 million in Q3 2025 and $9.0 million in Q2 2025.